Weight Maintenance with Litramine (IQP-G-002AS)‎: A 24-Week Double-Blind, Randomized, Placebo-Controlled Study

Abstract EN

Background.

Litramine (IQP-G-002AS) was shown to be effective and safe for weight loss in overweight and obese subjects.

However, long-term effectiveness on maintenance of body weight loss has yet to be ascertained.

Objective.

To assess effect of Litramine on maintenance of body weight loss.

Methods.

A double-blind, randomised, placebo-controlled trial on overweight and obese patients was conducted over two sites in Germany for 24 weeks.

Subjects with documented previous weight loss of 3% over the last 3–6 months were randomised to groups given either Litramine (3 g/day) or a matching placebo.

Primary endpoints were difference of mean body weight (kg) between baseline and end of study and maintenance of initially lost body weight in verum group, where maintenance is defined as ≤1% weight gain.

Results.

Subjects who were taking Litramine lost significantly more body weight compared to the subjects taking placebo who gained weight instead ( - 0.62 ± 1.55 kg versus 1.62 ± 1.48 kg, p < 0.001 ).

More importantly, 92% of subjects in Litramine group were able to maintain their body weight after initial weight loss, versus 25% in placebo group.

No serious adverse events were reported throughout.

Conclusion.

Litramine is effective and safe for long-term body weight maintenance.

Trial Registration.

This trial is registered with Clinicaltrials.gov identifier: NCT01505387.